Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.40, $0.01 better than the analyst estimate of $0.39. Revenue for the quarter came in at $180 million versus the consensus estimate of $183.3 million.

Myriad Genetics sees FY2015 EPS of $1.44-$1.46, versus prior guidance of $1.50-$1.55 and the consensus of $1.52. Myriad Genetics sees FY2015 revenue of $720-722 million, versus prior guidance of $730-740 million and the consensus of $734.19 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• Can global equities keep rising? UBS sees these factors driving upside